Articles tagged with Blocking Antibodies
Researchers at UMC Utrecht discovered that converting monoclonal antibodies from IgG to IgM isotype can significantly broaden their ability to recognize and bind multiple human-relevant bacterial pathogens. This finding could guide the future design of antibody therapies against bacterial infections.
A novel drug target, CD300a, has been identified to suppress immune cell activation and prevent chronic heart and kidney failure after acute tissue injury. The treatment preserves cardiac function and reduces renal fibrosis in mice with genetic deficiency of CD300a.
A study using cryo-electron microscopy revealed that autoantibodies in myasthenia gravis disrupt acetylcholine receptor function by blocking or activating the immune system's complement pathway. This knowledge helps explain treatment variability and offers a foundation for personalized therapies targeting specific antibody interactions.
Scientists from the University of Zurich created decoy molecules that bind to autoantibodies, preventing them from inhibiting type I interferons. This restoration restores antiviral effect on viruses like influenza, offering hope for treatment and reducing viral disease susceptibility.
The Chinese Medical Association has released updated guidelines for pediatric mycoplasma pneumoniae infection, emphasizing a multi-faceted diagnostic approach and evidence-based treatment strategies. The guidelines highlight the importance of accurate diagnosis and responsible antibiotic use to combat rising resistance.
Researchers found that older adults with weakened immunity developed fewer antibodies against RSV following vaccination compared to healthy individuals. The study suggests that adjuvant-enhanced vaccines could improve immune responses in immunocompromised people, warranting further investigation.
Researchers discovered that aggressive breast cancer prompts nearby immune cells to build 'molecular bridges' between themselves, suppressing the immune response. An antibody treatment that blocks these bridges was shown to restore the immune system's ability to attack with force, inhibiting tumor growth in a mouse model.
Researchers have discovered two human antibodies that can recognize and target proteins causing severe malaria. These broadly reactive antibodies may represent a common mechanism of acquired immunity to severe malaria, offering insights for the design of a PfEMP1-based vaccine or treatment targeting severe malaria. The breakthrough cou...
Researchers at Fred Hutchinson Cancer Center have made a breakthrough in understanding how protective antibodies can target malaria parasites. By analyzing the structure of these antibodies and their interaction with the parasite's protein, the team has identified a weak spot that could be targeted by vaccines to prevent severe disease.
Researchers from Kyushu University have developed an antibody that targets and prevents the dysfunction of hepatocyte growth factor (HGF), a critical protein for skeletal muscle development, regeneration, and repair. The new antibody, 1H42F4N, blocked nitration of HGF and did not disrupt its activity.
Researchers found that repeated mRNA vaccines enhance mucosal antibodies in nasal secretions, blocking viral entry and providing sustained protection. The immune responses generated by mRNA vaccines may persist longer than previously thought, offering hope for sustained protection against emerging COVID-19 variants.
Researchers at Emory University have discovered a family of enzymes that work to reduce IgG-mediated pathologies in diseases like Myasthenia Gravis. The newly found enzyme was used to treat various IgG-mediated pathologies in mice and found to be extremely effective, requiring only 4,000 times less of the enzyme than current treatments.
CAR-T cell therapy, a regenerative immunotherapy, has shown promise in treating blood cancers but struggles with T-cell exhaustion. Researchers have discovered that overproduction of the IL-4 protein causes this exhaustion and used CRISPR gene-editing technology to remove it, improving CAR-T cell therapy outcomes.
Researchers identified an antibody that assists some variants of the virus in infecting cells while blocking others, a dual-role effect. The study highlights the complexity of developing treatments as viruses evolve, but notes this phenomenon has not been observed in humans.
Researchers developed a monoclonal antibody called SC27 that targets multiple parts of the SARS-CoV-2 spike protein, including conserved sections. The antibody shows promise against various COVID-19 variants and related coronaviruses, potentially benefiting immunocompromised patients
Researchers at UT Austin have developed a broadly neutralizing plasma antibody called SC27 that can neutralize all known COVID-19 variants. This discovery was made possible by the technology of Ig-Seq, which provides a closer look at the antibody response to infection and vaccination.
New research published in The FASEB Journal shows that blocking CTLA-4 activates Th17 cells, increasing inflammation and damaging the heart. Inhibiting this activation reverses anti-CTLA-4-mediated heart damage.
Researchers at Karolinska Institutet have conducted a Phase 2 UNITY clinical trial involving pregnant women with a history of very severe HDFN. Nipocalimab was found to prevent and mitigate the disease without causing serious side effects in the mother or fetus.
Researchers at Johns Hopkins Medicine identified a potentially new biological target involving Aplp1, which drives the spread of Parkinson's disease-causing alpha-synuclein. The findings suggest targeting this interaction with drugs could slow Parkinson's disease progression and other neurodegenerative diseases.
Researchers developed Epitope Binning-seq to analyze epitopes in monoclonal antibodies. The method accurately classified antibodies into distinct epitope bins, providing valuable insights into their binding patterns and streamlining early antibody drug development.
Researchers identified how AML cells develop resistance to first-line treatments by up-regulating multiple signalling pathways. Targeting RAS family proteins shuts off this route, preventing cancer cell death.
Researchers at UVA Health discovered a potential explanation for long COVID symptoms by identifying 'abzymes' that act like enzymes regulating important bodily functions. This discovery could lead to new treatments targeting these rogue antibodies to alleviate acute effects of COVID-19 and its complications.
A new strategy used by cancer cells to protect themselves from immune system attack has been identified, and a potential target for immunotherapy has been found. Blocking activin receptor 1C on CD4+ T cells may help prevent the accumulation of immune-suppressing Tregs in tumors and slow tumor growth.
Researchers at Duke University have discovered a critical structure on the HIV virus that plays a crucial role in its infection process. By understanding this structure's dynamics, scientists may be able to design broadly neutralizing antibodies for an AIDS vaccine.
Cancer immunotherapy can cause severe colitis due to hyper-activated immune T cells and deleted regulatory T cells. Researchers at Michigan Medicine have identified a new mouse model that develops colitis after treatment with antibodies used for tumor immunotherapy, revealing the mechanism behind this side effect.
Researchers have identified a novel class of antibodies capable of neutralizing both certain H3 and H1 strains of the flu virus, with potential applications in developing more broadly protective flu vaccines. The findings could also contribute to reducing reliance on chicken egg-based manufacturing methods.
Researchers at Shimane University have found a way to prolong the therapeutic effects of botulinum toxin-A by blocking the insulin-like growth factor 1 receptor. This breakthrough could lead to reduced frequency and cost of injections, improving patient outcomes and convenience.
A study of over 2,300 patients found that HIV-1 neutralizing antibody response decreases over time but highly potent broadly neutralizing antibodies remain detectable. This finding suggests a possible permanent vaccine response and is an important step toward developing an effective HIV-1 vaccine.
A clinical trial found that high levels of anti-Ro/SSA antibodies in pregnant women are associated with an increased risk of fetal atrioventricular block (AVB), a condition that can be fatal. Home-based fetal heart rate monitoring reliably detects conduction abnormalities, potentially reducing the need for serial echocardiograms.
A new antibody created by Cold Spring Harbor Laboratory researchers may offer an effective treatment for some breast cancers. The antibody targets the PTPRD enzyme, which is overabundant in certain breast cancers and helps them spread.
A team of scientists has developed a method to detect active Cullin-RING ligases (CRLs), which are responsible for destroying unwanted proteins in cells. The new technology, called a molecular radar, reveals which CRLs are deployed to address cellular stresses and perform the actions of some anti-cancer drugs.
A study published in eBioMedicine identified the mechanism behind rapid vaccine waning in patients on TNF-α blockers for autoimmune diseases like Crohn's and rheumatoid arthritis. Regular booster vaccinations are crucial to maintain protection, especially for those receiving immunosuppressive therapy.
UCF researcher Dr. Justine Tigno-Aranjuez has discovered a new receptor that recognizes house dust mite allergens, opening up potential for broad-spectrum therapy. The finding could lead to improved treatments for common allergies, including asthma.
A new study by Cedars-Sinai Medical Center finds that people with long COVID-19 produce higher levels of antibodies against the virus than those without. The elevated antibody levels persist for months longer than expected after receiving a COVID-19 vaccine, sparking further research into the condition.
Researchers at Weill Cornell Medicine have identified an antibody that blocks infection by all dominant COVID-19 variants, including Omicron. The discovery could lead to new antibody-based treatments and more effective vaccines.
A new Northwestern University study suggests that COVID-19 boosters may be less effective due to pre-existing antibodies from initial vaccinations. The study found that these antibodies can rapidly clear the booster from the body, limiting its efficacy. Increasing time between vaccinations is also beneficial for the immune response.
Researchers highlight CD200's role in regulating immunosuppressive tumor microenvironments and propose alternative strategies for its neutralization. Unbiased genomic- and proteomic-based approaches may help clarify CD200 expression regulation across various human cancers.
Researchers at the Istituto di Ricerca in Biomedicina discovered coldspots within the coronavirus spike protein, which are remarkably conserved across variants. Antibodies targeting these coldspots showed promise in blocking virus infection and protecting against disease in preclinical models.
Research finds that individuals who received monoclonal antibodies before COVID vaccination exhibit a diverse antibody response, increasing the coverage provided by vaccines. This phenomenon, known as antibody feedback inhibition, is beneficial for diversifying immune responses to viruses.
Researchers at Texas A&M University engineered DARPins to block the interaction between the COVID-19 virus and host cells, significantly reducing disease progression. The nasal sprays showed effectiveness against various variants, including omicron, and could provide a lower-cost therapeutic option for those at high risk.
A study of 104 transgender and nonbinary youths found that gender-affirming care reduces depression and suicidal thoughts over 12 months. The treatment significantly improved mental health outcomes in the participants.
A new study found that the SARS-CoV-2 spike protein transforms human heart vascular cells into inflammatory cells, causing severe microvascular damage. Blocking antibodies could be a new treatment to alleviate cardiovascular complications in COVID-19 patients.
Scientists have developed a fusion protein that successfully blocks replication of SARS-CoV-2 and related viruses in cell culture tests. The protein combines ACE2 with human antibody fragments, providing reliable protection against future mutations.
Researchers deciphered the structure of a key protein complex in the human immune system, consisting of an antibody and its receptor. This discovery opens new avenues for therapies in allergies, autoimmune diseases, and transplantation medicine, enabling a better understanding of how pathogens are recognized and removed by immune cells.
A study found that antibodies in patients with primary Sjogren's syndrome bind to small nerve endings, blocking transmission and causing severe dryness of the eyes and mouth. Researchers hope to use this discovery to develop new treatments for autoimmune diseases.
A study by Jefferson researchers found that blocking the transforming growth factor-beta (TGF-beta) protein can prevent diabetic kidney disease in mice. The antibody treatment prevented kidney scarring and renal failure, offering hope for a new treatment option for humans with type 2 diabetes.
Researchers at Rockefeller University have discovered an immune-cell mechanism that boosts the potency of therapeutic antibodies. The finding could lead to more effective cancer treatments by manipulating the interaction between antibodies and Fc receptors on immune cells.
Researchers have developed an oral vaccine that protects rats' brains from stroke and prevents seizures, with significant protection for at least five months after a single dose. The vaccine targets the N-methyl-D-aspartate receptor, blocking it to prevent brain cell death and damage.
Poultry farmers can stop using antibiotics to promote growth in birds by adding antibodies against appetite-suppressing neurotransmitters and a fatty acid found in hamburgers. This alternative method produces similar growth gains as antibiotics, with improvements of 3-5% in growth rates.
The discovery of BLyS, a natural component of the immune system, holds promise for treating immune deficiency disorders, enhancing vaccine effectiveness, and targeting certain types of leukemia and lymphoma. The substance stimulates B cell growth and antibody production, addressing a long-standing puzzle about monocytes' role in the im...
ABX-EGF targets the receptor for human epidermal growth factor (EGFr), which is overexpressed on many major human tumor types. The antibody eradicates established tumors with low doses and has minimal immunogenicity.
Researchers discovered that auto-antibodies play a direct role in the development of multiple sclerosis by destroying myelin sheaths. The study, published in Nature Medicine, suggests that antibodies produced by B cells are responsible for breaking down myelin, a key component of nerve fibers.
Scientists have discovered that antibodies can recognize the orientation of amino acids, allowing them to bind only with specific handedness. This ability may be key to developing new, effective pharmaceuticals by identifying and sorting out left- and right-handed molecules.
Researchers at the University of Pennsylvania School of Medicine have discovered a new antibody that targets the CXCR4 receptor, a molecule involved in HIV infection. The antibody, termed 12G5, has been shown to block some types of HIV from infecting cells and has enormous value for HIV investigators.